Dublin, April 02, 2026 (GLOBE NEWSWIRE) — The “Medulloblastoma Drug Market Report 2026” has been added to ResearchAndMarkets.com’s offering. The report provides comprehensive insights, covering market size, regional shares, competitor analysis, and trends.
The global medulloblastoma drug market has experienced significant growth, with projections indicating a surge from $3.03 billion in 2025 to $3.28 billion in 2026, maintaining a robust compound annual growth rate (CAGR) of 8.3%. This expansion is driven by advancements in pediatric oncology, increased diagnoses, standardized chemotherapy protocols, the proliferation of cancer hospitals, and improved surgical outcomes.
Looking ahead, the market is poised to grow to $4.49 billion in 2030 at a CAGR of 8.2%. Growth factors include targeted brain cancer research, rising survival rates, investment in pediatric oncology, expansion of specialty centers, and funding for rare diseases. Noteworthy trends involve combination chemotherapy regimens, pediatric oncology focus, increased clinical trials for rare tumors, and advancements in targeted brain cancer therapies.
The rising prevalence of brain tumors is a key driver for market expansion. This increase is linked to better detection, aging populations, environmental factors, public awareness, and genetics. Medulloblastoma treatments, including chemotherapy and radiation, play a crucial role in tumor reduction and cancer cell elimination. For instance, the American Cancer Society reported 14,040 new brain and nervous system cancer cases in males and 10,780 in females in 2025, with 18,330 projected deaths, underscoring the urgent need for effective treatments.
Personalized medicine is set to propel market growth by tailoring treatments to individual genetic profiles. Advances in genomics and biotechnology have enhanced treatment outcomes and reduced side effects. In February 2024, the Personalized Medicine Coalition noted the FDA approved 16 new personalized therapies for rare diseases in 2023, up from six in 2022, with several targeting cancer, reflecting a shift towards precision therapies.
Escalating healthcare spending also boosts the market, driven by aging populations, medical innovation, chronic disease burdens, and rising administrative costs. In December 2024, the Centers for Medicare & Medicaid Services reported a 10.4% increase in hospital spending to $1.51 trillion, with prescription drug costs rising 11.4% to $449.7 billion. Increased spending supports medulloblastoma drug development through research and clinical studies.
Major companies in the market include Pfizer Inc., Novartis AG, Roche Holding AG, and others. In 2025, North America led the market, with Asia-Pacific expected to be the fastest-growing region. The report covers regions like Western and Eastern Europe, North and South America, the Middle East, and Africa, along with countries such as the USA, China, India, and Japan.
Reasons to Purchase:
- Experience a global viewpoint with coverage of 16 geographies.
- Interpret key macroeconomic influences, including geopolitical conflicts and evolving regulatory landscapes.
- Develop specific strategies based on detailed regional and country-specific data.
- Identify lucrative growth segments for investment opportunities.
- Leverage forecast data to outperform competitors and stay ahead of market trends.
- Understand customer demographics through end-user analysis.
- Benchmark against competitors focusing on market share, innovation, and brand strength.
- Evaluate total addressable market (TAM) and market attractiveness to gauge market potential.
- Use the high-quality data and analysis to support internal and external presentations.
- Receive regular updates with an Excel data sheet for streamlined data extraction and analysis.
Markets Covered:
- By Drug Candidate: Dianhydrogalactitol; Investigational Medicinal Product 5471; Ipilimumab; Indoximod; Other Types
- By Product: Chemotherapy Drugs; Targeted Therapy Drugs; Radiation Therapy Drugs
- By Route of Administration: Intravenous; Oral; Intrathecal
- By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retail Pharmacy
- By End-Users: Hospitals; Homecare; Speciality Centres; Other End-Users
Subsegments:
- Dianhydrogalactitol: Oral and Intravenous Formulations
- Investigational Medicinal Product 5471: Oral and Intravenous Formulations
- Ipilimumab: Monotherapy and Combination Therapy
- Indoximod: Oral and Combination Therapy
Companies Mentioned: Pfizer Inc., Novartis AG, Roche Holding AG, Bristol-Myers Squibb Company, Merck & Co. Inc., AstraZeneca plc, among others.
Countries: Australia, Brazil, China, France, Germany, India, and more.
Regions: Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa
Data: Includes ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Key Attributes
| Report Attribute | Details |
| No. of Pages | 250 |
| Forecast Period | 2026-2030 |
| Estimated Market Value (USD) in 2026 | $3.28 Billion |
| Forecasted Market Value (USD) by 2030 | $4.49 Billion |
| Compound Annual Growth Rate | 8.2% |
| Regions Covered | Global |
The companies featured in this Medulloblastoma Drug market report include:
- Pfizer Inc.
- Novartis AG
- Roche Holding AG
- Bristol-Myers Squibb Company
- Merck & Co. Inc.
- AstraZeneca plc
- Eli Lilly and Company
- Amgen Inc.
- Sanofi S.A.
- Bayer AG
- Eisai Co. Ltd.
- Teva Pharmaceutical Industries Ltd.
- Takeda Pharmaceutical Company Limited
- Ipsen S.A.
- Daiichi Sankyo Co. Ltd.
- Jazz Pharmaceuticals plc
- Sun Pharmaceutical Industries Ltd.
- Dr. Reddy’s Laboratories Ltd.
- Curtana Pharmaceuticals Inc.
- Biodexa Pharmaceuticals plc.
For more information about this report visit https://www.researchandmarkets.com/r/xvu2eo
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
- Medulloblastoma Drug Market
